Selecta Biosciences

480 Arsenal Way
Building One
Watertown
Massachusetts
02472
United States

Tel: 617-923-1400
Fax: 617-924-3454

About Selecta Biosciences

Selecta Biosciences, Inc. is a clinical-stage biopharmaceutical company that is focused on unlocking the full potential of biologic therapies by mitigating unwanted immune responses. Selecta plans to combine its tolerogenic Synthetic Vaccine Particles (SVPTM) with a range of biologics for rare and serious diseases that require new treatment options. The company's current proprietary pipeline includes SVP-enabled enzyme, oncology and gene therapies. SEL-212, the company's lead candidate in Phase 2, is being developed to treat severe gout patients and resolve their debilitating symptoms, including flares and gouty arthritis. Selecta's SEL-403 product candidate, a combination therapy consisting of SVP-Rapamycin and LMB-100, recently entered a Phase 1 trial in 2018 for the treatment of patients with malignant pleural or peritoneal mesothelioma. Selecta's proprietary gene therapy product candidates are being developed for rare inborn errors of metabolism and have the potential to enable repeat administration. The use of SVP also holds potential in the development of vaccines and treatments for allergies and autoimmune diseases. Selecta is based in Watertown, Massachusetts. For more information, please visit http://selectabio.com and follow @SelectaBio on Twitter.

Stock Symbol: SELB

Exchange: NASDAQ

157 articles with Selecta Biosciences

AskBio and Selecta Biosciences Receive Orphan Drug Designation for MMA-101 to Treat Methylmalonic AcidemiaGene therapy MMA-101 has obtained both orphan drug designation and rare pediatric disease designation from the FDA

11/19/2020

Asklepios BioPharmaceutical, Inc. and Selecta Biosciences, Inc. announced that the U.S. Food and Drug Administration has granted orphan drug designation to MMA-101, an AAV-based gene therapy in development for the treatment of isolated methylmalonic acidemia due to methylmalonyl-CoA mutase gene mutations.
AskBio and Selecta Biosciences Receive Orphan Drug Designation for MMA-101 to Treat Methylmalonic AcidemiaGene therapy MMA-101

11/19/2020

Asklepios BioPharmaceutical, Inc. (AskBio) and Selecta Biosciences, Inc. (NASDAQ: SELB) today announced that the U.S. Food and Drug Administration (FDA) has granted orphan drug designation to MMA-101, an AAV-based gene therapy in development for the treatment of isolated methylmalonic acidemia (MMA) due to methylmalonyl-CoA mutase (MMUT) gene mutations. MMA-101 previously received rare pediatric disease de
Selecta Biosciences to Participate in Upcoming Investor Conferences - Nov 10, 2020

11/10/2020

Selecta Biosciences, Inc. announced that Selecta’s Chief Executive Officer, Carsten Brunn, Ph.D., will participate virtually in the following investor conferences in November:
Selecta Biosciences Reports Third Quarter 2020 Financial Results and Provides Corporate Updates

11/5/2020

Phase 3 DISSOLVE clinical program with Sobi ongoing to evaluate SEL-212; topline data expected in the second half of 2022 IND filing for gene therapy expected in Q1 2021; preliminary Phase 1 data expected by end of 2021 IgA nephropathy program underway with IND expected by end of 2021 Ended quarter with cash position of $147.6 million with runway into the first quarter of 2023 Company to host conference call today at 8:30 a.m. ET
Selecta Biosciences to Host Conference Call and Webcast to Discuss Third Quarter Financial Results and Recent Operational Highlights

10/29/2020

Selecta Biosciences, Inc. (NASDAQ: SELB), a clinical-stage biotechnology company focused on unlocking the full potential of biologic therapies based on its immune tolerance platform technology, ImmTOR™, today announced that it plans to host a conference call on November 5, 2020 at 8:30 a.m. ET to discuss its financial results for the third quarter and recent operational highlights.
Selecta Biosciences and AskBio Receive FDA Rare Pediatric Disease Designation for their Gene Therapy for Methylmalonic Acidemia

10/20/2020

Selecta Biosciences, Inc. (NASDAQ: SELB) and Asklepios BioPharmaceutical, Inc. (AskBio), today announced the U.S. Food and Drug Administration (FDA) has granted Rare Pediatric Disease Designation to MMA-101 for the treatment of isolated methylmalonic acidemia (MMA) due to methylmalonyl-CoA mutase (MMUT) gene mutations
Selecta Biosciences and IGAN Biosciences Enter into Research License and Option Agreement to Study Selecta’s ImmTOR™ Immune Tolerance Platform in Combination with IGAN’s IgA Protease for the Treatment of IgA Nephropathy

10/8/2020

Application of ImmTOR™ plus IGAN’s IgA p rotease to target immunoglobulin A ( IgA ) deposition, the critical event leading to IgA N ephropathy ( IgAN ) Selecta’s IgA nephropathy program builds upon SEL-212 , which has demonstrated ImmTOR™ e ffective at tolerizing a highly immunogenic therapeutic enzyme Investigational New Drug (IND) application expected in Q4 2021 WATERTOWN, Mass., and BOSTON, Oct. 08, 2020 (GLOBE NEWSWIRE) -- Selecta Biosciences
Clinical Catch-Up: September 28-October 2

10/5/2020

Biopharma companies wrapped up September and headed into October with plenty of clinical trial news. Here’s a look.
Selecta Biosciences and Sobi Announce Topline Data of SEL-212 from the Phase 2 COMPARE Trial Supporting the Potential for Important Clinical Improvement in Patients with Chronic Refractory Gout

9/30/2020

Selecta Biosciences, Inc. (NASDAQ: SELB) and Swedish Orphan Biovitrum AB (publ) (Sobi™) (STO:SOBI), today announced topline data for the Phase 2 COMPARE trial comparing the efficacy of SEL-212, a combination of Selecta’s ImmTOR™ immune tolerance platform and a therapeutic uricase enzyme (pegadricase), to pegloticase (KRYSTEXXA®)
Selecta Biosciences to Participate in Upcoming Conferences

9/24/2020

Selecta Biosciences, Inc. (NASDAQ: SELB), a clinical-stage biotechnology company focused on unlocking the full potential of biologic therapies based on its immune tolerance platform, ImmTOR TM , today announced that Selecta’s Chief Executive Officer, Carsten Brunn, Ph.D., will participate virtually in the following investor conferences in October: Jefferies Virtual Gene Therapy/Editing Summit Date: Thursday, October 1, 2020 Fireside chat
Selecta Biosciences to Participate in Upcoming Investor Conferences - Sep 08, 2020

9/8/2020

Selecta Biosciences, Inc., a clinical-stage biotechnology company focused on unlocking the full potential of biologic therapies based on its immune tolerance platform, ImmTOR™, announced that Selecta’s Chief Executive Officer, Carsten Brunn, Ph.D., will participate virtually in the following investor conferences in September
Selecta Biosciences Secures Up To $35 Million Debt Financing with Oxford Finance LLC and Silicon Valley Bank

9/1/2020

Selecta Biosciences, Inc. (NASDAQ: SELB), a clinical-stage biotechnology company focused on unlocking the full potential of biologic therapies based on its immune tolerance platform, ImmTORTM, today announced that it has entered into a debt financing facility for up to $35 million with Oxford Finance and Silicon Valley Bank (SVB).
Selecta Biosciences Reports Second Quarter 2020 Financial Results and Provides Corporate Updates

8/6/2020

Closed strategic licensing agreement with Sobi for SEL-212 for $100 million in initial payments and up to $630 million in potential milestones, and tiered double-digit royalties Entered into research license and option agreement with Sarepta for the use of the ImmTOR™ immune tolerance platform in Sarepta’s gene therapy programs in certain neuromuscular diseases Gene therapy program in MMA in collaboration with AskBio on track to enter the clinic in the first half of 2021; preliminary data
Selecta Biosciences to Participate in Upcoming Investor Conferences

8/3/2020

Selecta Biosciences, Inc. (NASDAQ: SELB), a clinical-stage biotechnology company focused on unlocking the full potential of biologic therapies based on its immune tolerance platform, ImmTOR™, today announced that Selecta’s Chief Executive Officer, Carsten Brunn, Ph.D., is scheduled to participate virtually in the following investor conferences in August: William Blair Biotech Focus Conference Date: Thursday, August 6, 2020 Panel: 1:00
Selecta Biosciences Appoints Peter G. Traber, MD as Chief Medical Officer

8/3/2020

Selecta Biosciences, Inc., a clinical-stage biotechnology company focused on unlocking the full potential of biologic therapies based on its immune tolerance platform, ImmTOR™, announced the appointment of Peter G. Traber, MD, to the position of Chief Medical Officer.
Selecta Biosciences to Host Conference Call and Webcast to Discuss Second Quarter Financial Results and Recent Operational Highlights

7/30/2020

Selecta Biosciences, Inc. (NASDAQ: SELB), a clinical-stage biotechnology company focused on unlocking the full potential of biologic therapies based on its immune tolerance platform technology, ImmTOR™, today announced that it plans to host a conference call on Thursday, August 06, 2020, at 8:30 a.m. Eastern Time to discuss its financial results for the second quarter and recent operational highlights. Individuals may participate in the l
Sobi and Selecta announce closing of previously announced strategic licensing agreement for SEL-212, a phase 3-ready novel treatment for Chronic Refractory Gout

7/28/2020

Swedish Orphan Biovitrum AB announced that the strategic licensing agreement with Selecta Biosciences, Inc. for SEL-212, entered into as earlier announced on June 11, 2020, became effective on July 28, 2020, following the expiration of the Hart-Scott-Rodino Antitrust Improvements Act waiting period.
Selecta Biosciences to Present at the Raymond James 2020 Human Healthcare Innovation Conference

6/15/2020

Selecta Biosciences, Inc. (NASDAQ: SELB), a clinical-stage biotechnology company focused on unlocking the full potential of biologic therapies based on its immune tolerance platform, ImmTOR™, today announced that Selecta’s Chief Executive Officer, Carsten Brunn, Ph.D., will present at the Raymond James 2020 Human Healthcare Innovation Conference on Thursday, June 18 at 10:20 a.m. Eastern Time. A live webcast and a copy of the presentation
Selecta Biosciences to Present at the Jefferies 2020 Virtual Healthcare Conference

5/26/2020

Selecta Biosciences, Inc., a clinical-stage biotechnology company focused on unlocking the full potential of biologic therapies based on its immune tolerance platform, ImmTOR™, announced that Selecta’s Chief Executive Officer, Carsten Brunn, Ph.D., will present at the Jefferies Virtual Healthcare Conference on Tuesday, June 2 at 8:30 a.m. Eastern Time.
Selecta Biosciences Reports First Quarter 2020 Financial Results

5/7/2020

Selecta Biosciences, Inc. (NASDAQ: SELB), a clinical-stage biotechnology company focused on unlocking the full potential of biologic therapies based on its immune tolerance platform, ImmTOR™, today reported financial results for the first quarter ended March 31, 2020.